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INTRODUCTION  
 
 
Scope of the thesis. The work described in this thesis was performed in order to develop 
advanced analytical methods suitable to select and characterize Glycogen Synthase 
Kinase 3β  GSK- 3β inhibitors in vitro (both cell free assay and cell-based assay). GSK-
3β  is a proline-directed serine-threonine kinase that was initially identified as a 
phosphorylating and an inactivating agent of glycogen synthase, then found as one of the 
key enzyme in neurodegenerative diseases (ND).  Increased GSK-3β signaling, as found 
in Alzheimer disease (AD), not only leads to tau hyperphosphorylation, that is a 
prerequisite of Neurofibrillary Tangles (NFT), but also plays a direct role in several 
features of ND as modifying the axonal transport, enhancing toxic amyloid peptide 
production,  inducing  long term depression (LTD) and preventing memory formation [1].  
Therefore, GSK-3β is recognized as a key target for the development of new therapeutic 
agents for AD.  
Chapter 1. In order to select new potent and selective GS- 3β  inhibitors by using in vitro 
cell free assay, we validated an UHPLC-UV-Vis diode arrays detector (DAD) method for 
the very fast identification (resolution in less than 2 min) and determination of adenosine 
diphosphate (ADP) and adenosine triphosphate (ATP) in enzyme-based assay containing 
GSM-S synthetic peptide, ATP and GSK-3β.  At present, there are a wide variety of 
indirect kinase assays that can be used to measure inhibition [2,3].  To overcome the 
drawbacks often associated to indirect methods, we aimed to a fast, direct and selective 
methodology, suited to monitoring in parallel ATP and ADP, in view of a more detailed 
description of the enzymatic reaction and for accurately describing the mechanism of 
action of potential inhibitors. By using this method, selected inhibition hits will be 
characterized by defining their competitive mode of action with the substrate rather than 
with the ATP cofactor, in view of the discovery of compounds endowed of an increased 
GSK-3β selectivity over other protein-kinases. 
Chapter 2. Next, in order to verify that selected GSK-3β inhibitors can exert their 
neuroprotective effects also in cell-based assay, we choose histones acetylation as 
biomarker, hypothesizing that GSK-3β could be directly involved in the regulation of  
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histone acetylation through Histone deacetylase (HDAC) protein. Our hypothesis 
accounts that inhibition of GSK-3β, which leads to reduced HDAC activity [8], could 
restores the acetylation level in histones, protecting against neurodegeneration. 
Interestingly, GSK-3β could be highly considered a critical node in the progression of AD 
and targeting its inhibition could lead to the inhibition of NFT and peptide β-amyloid [9] 
and to the restoring of histone acetylation level necessary for normal neuronal activity.  
The N-terminal tails of histones are subject to many enzyme–mediated post-translational 
modifications (PTMs) such as lysine acetylation that result in changes in the accessibility 
of DNA to transcription factors and in subsequent protein-protein interactions. The most 
thoroughly studied PTM is the acetylation of four universally conserved lysine residues 
K5, K8, K12, and K16 located within the amino-terminal tail of histone H4, which plays 
a role in epigenetic regulation in several important cellular events or diseases as cancer 
and Alzheimer disease (AD).  Histone acetylation in particular has been shown to be 
important both in hippocampal long term potentiation (LTP) and memory formation in 
mice and both aging and AD pathology are associated with loss of histone acetylation 
(H4/H3) [4,5]. Therefore, quantification of histone modifications on individual lysine 
residues is of crucial importance to understand their role in cell biology and the loss of 
learning induced deacetylation at specific histone sites may represent biomarkers for 
memory loss and AD. 
Chapter 3. This chapter describes a targeted liquid chromatography mass spectrometry 
(LC-MS) method developed for the site-specific quantification of lysine acetylation in the 
N-terminal region of histone H4 from macrophage-like cell line RAW 264.7, with the 
perspective to apply the method on murine primary neurons upon administration of GSK-
3β inhibitors. During the last decade Mass-Spectrometry (MS) became the most widely 
used technique to study histone post-translation modifications (PTMs), and has been 
applied to study the effect of inhibitors in cell culture [6,7]. However, the frequent 
occurrence of lysine residues in the N-terminus of histone H4 hampers the quantification 
of acetylation on specific lysine residues using current approaches based on protein 
labelling and digestion with a single protease like trypsin.  The analytical strategy we 
developed shows that careful optimization of chemical derivatization steps at the protein 
and at the peptide level, combined with a more extensive digestion using chymotrypsin 
and trypsin, allows to differentiate between acetylation levels of each lysine residues. 
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Abstract 
 
Altered GSK-3β activity can contribute to a number of pathological processes including 
Alzheimer’s disease (AD). Indeed, GSK-3β catalyzes the hyperphosphorylation of tau protein 
by transferring a phosphate moiety from ATP to the protein substrate serine residue causing 
the formation of the toxic insoluble neurofibrillary tangles; for this reason it represents a key 
target for the development of new therapeutic agents for AD treatment. 
Herein we describe a new selective UHPLC methodology developed for the direct 
characterization of GSK-3β kinase activity and for the determination of its inhibition, which 
could be crucial in AD drug discovery.  
The UHPLC–UV (DAD) based method was validated for the very fast determination of ATP 
as reactant and ADP as product, and applied for the analysis of the enzymatic reaction between 
a phosphate primed peptide substrate (GSM), resembling tau protein sequence, ATP and GSK-
3β, with/without inhibitors. Analysis time was ten times improved, when compared with 
previously published chromatographic methods. The method was also validated by 
determining enzyme reaction kinetic constants (KM and vmax) for GSM and ATP and by 
analyzing well known GSK-3β inhibitors. Inhibition potency (IC50) values for SB-415286 (81 
± 6 nM) and for Tideglusib (251 ± 17 nM), found by the newly developed UHPLC method, 
were in good agreement with the luminescence method taken as independent reference method. 
Further on, the UHPLC method was applied to the elucidation of Tideglusib mechanism of 
action by determining its inhibition constants (Ki). In agreement with literature data, Tideglusib 
resulted a GSM competitive inhibitor, whereas SB-415286 was found inhibiting GSK-3β in an 
ATP competitive manner. This method was applied to the determination of the potency of a 
new lead compound and was found potentially scalable to inhibitor screening of large 
compounds collections.  
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1. Introduction 
 
Glycogen synthase kinase-3 (GSK-3) is an ubiquitous serine/threonine kinase first identified 
as one of several protein kinases that phosphorylated and inactivated glycogen synthase [1], 
the final enzyme in glycogen biosynthesis. Microtubule binding tau protein is a target of the 
GSK-3β isoform and has been demonstrated that increased GSK-3β signaling, as found in 
Alzheimer disease (AD) leads to tau hyperphosphorylation, a prerequisite for Neurofibrillary 
Tangles (NFT) formation.  moreover, modifying the axonal transport, enhancing toxic amyloid 
peptide production, inducing long-term depression (LTD) and preventing memory formation, 
it also plays a direct role in several features of neurodegeneration (ND) [2-12]. Therefore, 
GSK-3β is recognized as a key target for the development of new inhibitors as potential 
therapeutic agents for neurodegenerative disease, including AD.  
GSK-3 kinase is highly conserved throughout evolution and, in mammals, is encoded by two 
genes, GSK-3α and GSK-3β, which give rise two isoforms, 51 and 47 KDa respectively, which 
display a high degree of sequence identity at the level of their catalytic domain (98%) while at 
their N- and C- terminal regions  the overall identity corresponds to 85% [13]. The two isoforms 
are not functionally redundant, as demonstrated by the gene knock-out studies [14], suggesting 
that they might have different physiological functions [15]. In adulthood, GSK-3α and GSK-
3β are most prominently expressed in the brain with particular abundance in hippocampus, 
neocortex, and cerebellum [16]. An alternative splice variant of GSK-3β, GSK-3β2, is a 
neuron-specific splicing isoform containing a 13 amino acid insertion in the catalytic domain 
[17]. 
In neurons, GSK-3β is intimately involved with control of apoptosis, synaptic plasticity, axon 
formation, and neurogenesis [2-8]. In vivo studies indicate that abnormal activity of GSK-3β is 
a key contributor to deficits in memory formation and neurodegeneration in AD.  Transgenic 
animals that overexpress GSK-3 display alterations in brain size, impaired long-term 
potentiation (LTP), and deficits in learning and memory [9-12]. These animals also have 
features typical of AD such as hyperphosphorylation of tau protein, a prerequisite of 
neurofibrillary tangle (NFT), and enhanced production of Aβ peptide [9, 18-20]. Therefore, 
GSK-3β has attracted significant attention as a therapeutic target for the treatment of those 
disorders. In the last years a significant effort has been made to find highly selective GSK-3β  
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inhibitors both as potential therapeutic agents, able to modulate this abnormal activity, and as 
tools to understand the molecular basis of these disorders.  
At present, a wide variety of assays are employed to evaluate GSK-3β inhibition. However, 
ATP-dependent assay as bioluminescent read-outs is an indirect method, where an additional 
enzyme (luciferase) is used to detect the degree of phosphorylation, without discriminating 
between substrate and product [21]. Radioassay is another approach to assess 
hyperphosphorylation of primed substrate by GSK-3β, but it is not scalable to high-throughput 
screening of large compound collections and has significant issues related to the use and 
disposal of radioactive materials [22]. Fluorescence plate readers are typically used for 
inhibitors screenings, nevertheless this technique presents  limitations: false positive (inhibitors 
that fluoresce) false negative (inhibitors that quench fluorescence) [23]. 
Based on these considerations, we aimed to develop an accurate quantitative enzyme assay that 
does not require chromophore or radiolabelling and can be considered an useful analytical tool 
in numerous applications, particularly in the discovery of novel enzyme inhibitors, as potential 
leads for the treatment of AD. Therefore, we focused our attention on the development of a 
selective methodology suited to specifically monitoring ATP and ADP, cofactors in the GSK-
3β catalyzed phosphorylation reaction of the primed peptide (GSM peptide), which resembles 
the protein sequence substrate (Fig.1).  
In order to accomplish this aim, we validated an UHPLC-diode arrays detector (DAD) method 
for the very fast identification (resolution in less than 2 min) and determination of ADP and 
ATP in the enzymatic reaction containing GSM, ATP and GSK-3β with/without inhibitors.   
By using this validated method, selected inhibition hits were characterized by defining their 
potency and competitive mode of action with either the substrate or with the ATP cofactor, in 
view of the discovery of compounds endowed of an increased GSK-3β selectivity over other 
protein-kinases. Moreover, to gain a more detailed description of the enzymatic reaction for 
highlighting the mechanism of action of potential inhibitors, the UHPLC method was validated 
for inhibition studies, by testing two GSK-3β inhibitors, SB-415286 and Tideglusib, well 
known in literature for their potency and mechanism of action [24, 25]. 
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Fig.1 GSM synthetic peptide sequence based on muscles glycogen synthase 1 where pS 
corresponds to phosphorylated Serine residue. The presence of primed phosphorylation 
enhance the substrate affinity. The SXXXpS motif is specifically recognized by GSK-3β that 
phosphorylates the S residue by transfer of a phosphate moiety from ATP. 
 
 
 
 
2. Experimental    
 
2.1 Reagents and materials 
GSK-3β enzyme (cod.14-306) and synthetic peptide GSM were purchased from Merck 
Millipore (Darmstadt, Germany). Kinase-Glo Luminescent Kinase Assay was obtained from 
Promega (Promega Biotech Iberica, SL). 
Adenosine 5’-diphosphate (ADP) disodium salt, adenosine 5’-triphosphate (ATP) disodium 
salt hydrate, ammonium acetate, ammonium hydroxide, 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES), Ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic 
acid tetrasodium salt (EGTA), Ethylenediaminetetraacetic acid (EDTA), dimethyl 
sulfoxide (DMSO), and 3-[(3-Chloro-4-hydroxyphenyl) amino]-4-(2-nitrophenyl)-1H-pyrrol-
2,5-dione  SB-415286 inhibitor were purchased from Sigma-Aldrich (St. Louis, MO, USA).  
Tideglusib was purchased by Selleckem (Houston, USA). Magnesium acetate tetrahydrate, 
sodium phosphate dibasic and tetrabutylammonium bisulfate (TBA) were purchased from  
Merck Millipore, (Darmstadt, Germany). 
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All other reagents were of analytical grade and filtered by nylon membrane filters 0.40 µM 
(Merck Millipore Darmstadt, Germany). Ultrapure water was obtained on a Purite LTD water 
purification systems (Thame, UK) 
 
2.2. Standard Solutions  
Stock standard solutions of ATP and ADP (1 mM) were prepared in 6 mM ammonium acetate 
1.6 mM magnesium acetate pH 7.4 buffer (buffer A). Stock standard solutions of 1 mM GSM 
and 100 ng/μl GSK 3β were prepared in the buffer A, divided in aliquots and stored at -80°C. 
The GSM substrate resulted stable for six months. GSK-3β maintained its activity for one 
month after a single cycle of thawing. Further dilutions were prepared daily with fresh buffer 
A. The inhibitors were dissolved in DMSO in order to obtain 1 mg/mL stock solutions stored 
at -20°C. The stock solutions were diluted to the desired concentration with buffer A, in order 
to keep the percentage of DMSO below 1% value. The stock solutions resulted stable for more 
than six months.   
 
2.3 Chromatographic conditions 
The UHPLC/UV analysis was carried out by using a Jasco X-LC (JascoEurope, Cremella, 
Italy), including a binary pump (3185PU), autosampler (3059AS), a thermostated column 
compartment (3067C0), a degasser module (3080DG) and a Detector X-LC 3110 MD diode 
array (DAD). Instrument control, data acquisition, and processing were performed with 
software CromNAV Control Center. A reversed phase column (Kinetex 1.7 µm, C8, 100Å, 50 
x 2.1 mm, Phenomenex, United State) was equilibrated with a mobile phase consisting of buffer 
containing 20 mM sodium phosphate (pH 7.0) and 5mM tetra-n-butylammonium / methanol 
(85/15) (v/v).  Optimized chromatographic separation of ATP and ADP was carried out under 
isocratic conditions with a flow rate of 0.4 mL/min and the column oven set at T= 50°C. The 
eluent was monitored at 260 nm for nucleotide detection with a UV-DAD set in the range 210-
450 nm. 
In order to optimize the chromatographic conditions, pH buffer, TBA and phosphate 
concentrations and flow rate were investigated and optimized. Van Deemter plot was obtained 
by plotting theoretical plate height (H) versus flow rate. H was determined by H=L/N, dividing 
the length of the column by the number of plates N. N was determined from the  
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chromatographic data by applying the following formula N= 16 (Rt/w)2 where Rt= retention 
time of ADP/ATP; w=chromatographic peak width. 
 
2.4 UHPLC Method validation 
The method calibration and validation was performed on standard mixtures. For all the 
calculations, the analyte concentration was defined in terms of µM concentration of the injected 
volume (1 µL). Calibration curves were plotted for the ATP and ADP reference standards by 
performing UHPLC-UV analysis in triplicate on five incremental dilutions of the stock 
solutions. The concentration range for ADP and ATP were 0.5-10 µM, 0.25-250 µM, 
respectively. Calibration graphs were obtained by plotting the ADP and ATP peak areas, versus 
the corresponding analyte concentration. The detection limit (LOD, S/N=3) and quantification 
limit (LOQ, S/N=10) were also determined by performing UHPLC-UV analysis in triplicate 
on incremental dilutions of the standard mixture and real GSK3-β assay sample.  
To verify the accuracy of analyses, ATP and ADP respectively were added to the individual 
enzymatic solution and substrate. 
 
2.5. GSK 3β Activity Assay and kinetic studies by UHPLC 
The activity of GSK 3β was determined by measuring the formation of ADP. The buffer, used 
to measure the enzymatic activity, contained 6 mM ammonium acetate pH 7.4, 1.6 mM 
magnesium acetate, 1% DMSO. Spontaneous hydrolysis of ATP and interference from enzyme 
solution and buffer were accounted by preparing the corresponding blanks. Assay solutions µL 
consisted of GSK-3β (2.5 ng µL-1), ATP (250 µM) cofactor, GSM (250 µM) substrate, final 
volume 40 µl. The reaction was initiated with the addition of the enzyme. The mix solutions 
were shaken for 10 seconds at 300 rpm and activity assays were carried out in the Termomixer 
equipment (Eppendorf, Hamburg, Germany) at 30oC for 30 min. After incubation, assay 
reactions were stopped adding 40 µL of methanol. An additional 40 µL volume of mobile phase 
buffer for chromatographic analysis was further added to the assay reaction. An aliquot of 1 
µL of the reaction mixture was injected into the chromatograph under the chromatographic 
conditions described in section 2.3. 
The extent of the enzymatic conversion was monitored by following the increase in ADP 
chromatographic peak area. The samples containing only ATP in buffer A were incubated and 
injected into UHPLC system as reaction blank. The amount of ADP obtained from ATP 
spontaneous hydrolysis was subtracted in the enzymatic assay samples. Enzymatic activity was  
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calculated by determining the amount of ADP, interpolating the ADP peak area in its 
calibration curve, which was produced in 30 min incubation time.Kinetic constants (KM and 
vmax) values for GSK3β were determined by injecting in duplicate under the chromatographic 
conditions 1 μL aliquots of enzymatic mixtures.  The dependence of enzymatic activity on ATP 
and GSM was investigated by assaying both ATP and GSM in the concentrations ranging from 
0 µM to 250 µM. The parameters for ATP were determined under saturating conditions of 
GSM (250 µM) and the parameters for GSM were determined using saturating concentrations 
of ATP (250 µM). By plotting the picomoles of ADP formed per minute (v) versus the GSM 
substrate or ATP cofactor concentrations, Michaelis–Menten and Lineweaver-Burk plots were 
obtained and KM, Ki and Vmax values evaluated [26].  
 
2.6 GSK-3β Inhibition study  
2.6.1 IC50 determination by UHPLC 
The inhibition studies  were  performed  by setting the assay solutions, composed of  2.5 ng/µL 
GSK-3β, 250 µM GSM substrate and 250 µM ATP, in presence of increased concentrations of 
the inhibitors SB-415286 and Tideglusib. Incubation time, final solution assay volume and 
temperature were set up as for the kinase assay above described in section 2.5. 
The assay solutions containing increasing inhibitor concentration and a fixed GSM and ATP 
concentrations were then injected into the chromatographic system and the ADP peak areas 
integrated (Ai). 
The peak areas were compared with those obtained in absence of inhibitor and % inhibition, 
due to the presence of increasing test compound concentration, was calculated by the following 
expression: 100−(Ai/A0 × 100) where Ai is the ADP peak area calculated in the presence of 
inhibitor and A0 is the peak area obtained in the absence of inhibitor. Inhibition curves were 
obtained for each compound by plotting the % inhibition versus the logarithm of inhibitor 
concentration in the assay solution. The linear regression parameters were determined for each 
curve and the inhibitor concentration that reduces at 50% the enzyme maximum velocity (IC50) 
was extrapolated. 
 
2.6.2. Determination of steady-state inhibition constant (Ki) and inhibitors mechanism of 
action by UHPLC 
To obtain estimates of the ATP or GSM competitive inhibition constant Ki, reciprocal plots of 
1/v versus 1/[GSM] were constructed at relatively low concentration of substrate by injecting  
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in duplicate enzymatic mixture containing either GSM (15-125 μM) and ATP (250 μM), 
increasing covalent inhibitor concentrations, and using the chromatographic conditions 
reported in Section 2.3.  Product formation rates (v) were estimated by integrating the resulting 
ADP peak areas. The plots were assessed by a weighted least-squares analysis that assumed 
the variance of v to be a constant percentage of v for the entire data set. Slopes of these 
reciprocal plots were then plotted against inhibitor concentration and Ki was determined as the 
ratio of the replot intercept to the replot slope.Mechanism of action was evaluated by 
qualitatively comparing Lineweaver–Burk plot trends to the theoretical ones [27]. 
 
2.6.3 GSK-3β inhibition by luminescence assay 
The method of Baki et al [21] was followed to analyze the inhibition of GSK-3β. Assays were 
performed in 50 mM HEPES, 1 mM EDTA, 1 mM EGTA, and 15 mM magnesium acetate pH 
7.5 assay buffer using white 96-well plates. In a typical assay, 10 μL of test compound 
(dissolved in DMSO at 1 mM concentration and diluted in advance in assay buffer to the 
desired concentration) and 10 μL (20 ng) of enzyme were added to each well followed by 20 
μL of assay buffer containing 25 μM substrate and 1 μM ATP. The final DMSO concentration 
in the reaction mixture did not exceed 1%. After a 30 min incubation at 30 °C, the enzymatic 
reaction was stopped with 40 μL of Kinase-Glo reagent. After 10 min., luminescence in the 
entire visible range was recorded using a Victor™ X3 Perkin Elmer multimode reader. The 
activity is proportional to the difference of the total and consumed ATP. The inhibitory 
activities were calculated on the basis of maximal kinase and luciferase activities measured in 
the absence of inhibitor and in the presence of reference compound inhibitor SB-415826, [24] 
at total inhibition concentration, respectively. The linear regression parameters were 
determined and the IC50 extrapolated (GraphPad Prism 4.0, GraphPad Software Inc.). 
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3. Results and discussion  
 
The in vitro GSK-3β catalysed reaction is described in Fig.1. GSM is a synthetic peptide 
substrate, based on muscle glycogen synthase1, in which (pS) corresponds to the 
phosphorylated serine residue. The GSK-3β recognized sequence brings a serine/threonine at 
four amminoacids distance from a phosphorylated serine (Serine/Threonine)XXX(pSerine), a 
motif that represents an ideal model of target primed substrate for GSK-3β. In fact GSK-3β 
requires primed phosphorylation of the majority of its substrates and recognizes specifically 
the (S/T)XXX(pS) motif, whereby the first priming phosphorylation event is performed by 
another kinase in vivo andoccurs at the serine/threonine located after four amminoacids at N- 
terminal of the peptide sequence. Since ATP is consumed during the GSK-3β catalysed transfer 
of one phosphate moiety to the peptide substrate, giving rise to ADP, we developed a fast 
UHPLC method for the analysis of the enzymatic reaction by determining the amount of ADP. 
 
3.1 UHPLC-DAD chromatographic method. Optimization and validation. 
We previously reported the development and optimization of an ion exchange liquid 
chromatography (LC) method for the determination of ATP, ADP and AMP [28]. Separation 
of the nucleotides was achieved in a 15-min run by using a disk shaped monolithic ethylene 
diamine stationary phase, under a three-solvent gradient elution mode and UV detection. The 
described method resulted highly specific but not suitable for high-throughput screening due 
to the long gradient elution run time. 
Here the application of UHPLC technology allowed the determination of GSK-3β in vitro 
kinetics, and the possibility of developing a fast automated analysis of potential inhibitor 
collection. The developed chromatographic UHPLC method is based on the use of a C8 
stationary phase packed with sub-2-μm particles [29], under ion pairing conditions. Elution of 
the ATP and ADP was obtained in less than 2 min, keeping the same resolution when compared 
to HPLC analysis performed with both monolith and column packed with conventional particle 
sizes [30].  
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Mobile phase composition and flow rate were optimized in order to achieve high selectivity, 
high resolution values and suitable analysis time, by injecting standard mixtures of adenosine 
nucleotides. 
In this ion-pair HPLC method, we confirmed that the separation of negatively charged ATP 
and ADP is achieved due to either (1) the modification of the column’s surface by reversible 
binding of TBA, a large hydrophobic cations, or (2) to the binding of the ion pair complex of 
the cation with oppositely charged species formed in the mobile phase to the hydrophobic 
stationary phase [31, 32]. In order to elucidate the retention mechanism, different mobile phase 
compositions (phosphate ions and TBA concentration, percentage of the organic modifier) on 
ADP and ATP retention times and resolution were investigated. The obtained chromatographic 
data suggests the phosphate competition with the nucleotides anions distribution on the TBA 
modified stationary phase, under an ion-exchange mechanism [33]. This mechanism is in 
agreement with the higher retention time of ATP, which bears one phosphate moiety more than 
ADP. Since the increasing of the organic modifier percentage results in ADP and ATP 
decreased retention times, an alternative ion-pair mechanism can be invoked to explain the 
retention behavior of such compounds.  
Flow rate optimization was carried out determining the H trend at various flow rate. The 
construction of plate height curve [34] was performed by injecting fixed ADP/ATP 
concentration at increasing flow rate. The obtained graph showed that the best flow rate was 
0.4 mL/min (Fig. 2), because the minimum  H value was reached, indicating the highest plate 
number i.e. the best efficiency.  Baseline resolution of the two analytes plus AMP, was obtained 
under the optimised conditions, with a mobile phase consisting of buffer solution containing 
20 mM sodium phosphate (pH 7.4) and 5 mM TBA and methanol (85:15 v/v); column oven 
was set at 50°C in order to reduce solvent mixture viscosity and UV detection at 260 nm., 
maximum absorption wavelength for both compounds. Representative chromatogram of ATP 
and ADP separation is shown in Fig. 3. Peak identification was performed by comparing 
retention times of the standard solutions and peak apex UV spectra.    
The method linearity was estimated by plotting the obtained peak area of each analyte  versus 
the corresponding analyte concentration expressed as µM.  The calibration curves for ADP and 
ATP were found linear (r2 = 0.998 for both) and were described by the equations y = 1335.6 x 
+ 334.04 for ADP and y = 1494.1 x + 282.62 for ATP (n = 3). Limit of Detection (LOD) for 
ADP was found to be 0.75 ± 0.18 µM from the linear regression equation (3 x b/s, where b is  
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the y-intercept and s is the slope). Limit of Quantification (LOQ) was determined as 2.25 ± 
0.54  µM by 3*LOD.  
 
 
 
 
 
 
 
 
 
 
Fig. 2 Van Deemter plot relates plate height (H) to linear velocity of mobile phase (u) at 50°C 
column temperature. 
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Fig. 3 Representative chromatogram for ADP (60µM) and ATP (60µM) separation. The 
standard solution was analysed under chromatographic conditions described in section 2.3. 
 
  
 
 
3.2 GSK-3β kinetic studies by UHPLC  
The experimental conditions to perform the GSK-3β kinetic studies in vitro were developed by 
determining the substrate and cofactor kinetic constants KM and Vmax. The determination of the 
activity and kinetic parameters of GSK-3β was carried out in buffer A, that was found to be the 
optimum buffer compatible for UHPLC analysis. Substrate, cofactor and enzyme were 
incubated for 30 min at 30°C and injected into the UHPLC system, under the chromatographic 
conditions reported in section 2.3, after the previous addition of 40 µL of methanol and 40 µL 
of chromatographic buffer. GSK-3β activity was determined by following the conversion of 
ATP into ADP. The amount of ADP was determined by interpolating its peak area into the 
calibration curve. ADP production was correlated to substrate or cofactor to obtain Michaelis–
Menten plots for ATP and GSM.  
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Optimum enzyme concentration and incubation time were respectively found to be 2.5 ng/µL 
and 30 minutes, by injecting the kinase assay solution at increasing concentration of the enzyme 
(range 0-5 ng/µl) and at increasing incubation time (range 15-120 min) (data not shown).  
ATP and GSM concentrations varied independently in order to ascertain the saturating 
conditions for substrate and cofactor. Under the experimental conditions, the saturating 
concentrations for ATP and GSM were 250 µM and 250 µM, respectively. .  
The Km and Vmax values for ATP/GSM were determined by plotting the enzyme activity, by 
means of the ADP picomoles min-1, versus the ATP or GSM concentration of the assay (Fig. 
4). By using a non linear fitting with the equation: Y = Bmax * X/(Kd+X), the kinetic constants 
values were obtained in good agreement with literature [35] and reported in Table 1. 
 
 
 
 
 
 
Fig. 4 Michaelis–Menten plots showing the rate of GSK-3β catalysis. ADP pmol min−1 vs. 
injected GSM or ATP concentrations are showed in plot a and b respectively 
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*Data obtained by the luminescence method [21] 
 
 
Table 1  Kinetic constants for GSM and ATP obtained by the UHPLC method. Data reported 
are the mean of two independent measurements, each performed in duplicate. 
 
 
 
 
 
3.3 Kinetics analysis of GSK-3β inhibition 
The developed UHPLC method for GSK-3β kinase activity based assay was tested to evaluate 
the GSK-3β inhibition by using two well-known inhibitors. In order to validate our method, 
reference inhibitors with known potency and mechanism of action were chosen: SB-415286 
(Fig. 5a), is a maleimide derivative and cell permeant small-molecule that has showed in vitro 
potent and selective GSK-3β inhibition in an ATP competitive manner [24].  Further data have 
revealed the role of SB-415286 to prevent neuronal death. At this regard, SB-415286 has 
shown the capability to protect primary neurones from death induced by reduced 
phosphatidylinositol 3-kinase pathway activity [37]. The second tested compound is Tideglusib 
(Fig 5b), well known in literature to be a potent, irreversible and non ATP competitive GSK-
3β inhibitor [27]. 
 
  
 GSM ATP 
KM (µM) 
17 ± 3 
25* 
20 ± 2 
>3* 
vmax (pmoles/min.) 
18.8 ±8 
 
13.3 ±8 
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Fig. 5  GSK-3β inhibitor structures: a SB-415286 ATP competitive inhibitor, b Tideglusib non 
ATP-competitive inhibitor  and c EC7 novel GSK-3β inhibitor. 
 
 
 
The IC50 of the two known inhibitors (Tideglusib and SB-415286), whose potency is in the low 
micro molar range, was assessed by extrapolation from the inhibition curves (Fig. 6). The 
inhibition curves were obtained by incubating GSK-3β with simultaneously both the GSM and 
ATP at a fixed saturating concentration, as determined by the Michaelis–Menten plot, and 
inhibitors at increasing concentration. Increasing reduction of the ADP peak area (i.e. inhibition 
of enzyme rate of hydrolysis), when compared to the area obtained by the sole substrate and 
cofactor, was obtained for increasing inhibitors concentration (Fig. 7). The percent inhibition 
was plotted against the logarithm of inhibitor concentration to obtain the inhibition curves. The 
IC50 values was obtained by interpolation in the inhibition curve. 
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Fig. 6  Non -Linear regression analyses obtained by plotting inhibition of ATP catalysis versus 
increasing SB-415286 inhibitor concentrations by UHPLC analyses. 
 
 
 
 
 
Fig.7  Overlaid chromatograms obtained after injection of reaction mix solutions prepared as 
described in section 2.5 plus increasing inhibitor concentration. The solid line chromatogram 
is relative to GSK-3β activity. Overlaid decreasing ADP peaks for reaction mixtures containing 
increasing inhibitor concentration (dashed lines). 
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The IC50 values obtained in the UHPLC method were compared with the values obtained with 
the luminescence method and a valid correlation was obtained (Table 2), SB-415286 being a 
three times stronger inhibitor than Tideglusib. This validation allows a direct comparison 
between UHPLC inhibition potencies and IC50 values determined with the reference 
luminescence method. Further on, the results indicate that the UHPLC method can be used for 
the on-line screen of new GSK-3β inhibitors.  
 
 
Luminescence 
method 
UHPLC method 
 IC50 (nM)±SEM IC50 (nM)±SEM 
SB-415286 70 ±8 81 ± 6 
Tideglusib 200 ± 15 251 ± 17 
 
Table 2. Inhibitors’ potencies obtained with the reference luminescence and new UHPLC 
methods. 
 
 
 
The mechanism of action of SB-415286 inhibition was further investigated by carrying out the 
inhibition experiment at a lower concentration of ATP (125 µM). The resulting IC50 values of 
45 ± 5 nM confirmed a clear mechanism of ATP competition. [24]. In fact a lower IC50, (higher 
potency of inhibition) is observed in the presence of a lower ATP concentration, indicating a 
competition for the same site on the enzyme. 
Conversely, Tideglusib showed a competitive mechanism of inhibition with the substrate 
GSM. In fact, its IC50 value was found to be 250 ± 17 nM at ATP 250 µM, whereas, at 125 and 
62.5 µM GSM concentrations, its potencies were found respectively 15 ± 0.6 nM and 5 ±1 nM,  
In Fig.8, Lineweaver–Burk plots obtained for Tideglusib is reported as an example of substrate 
GSM competitive mechanism of action. Reciprocal plots for Tideglusib inhibition showed 
unvaried Vmax and increasing x-intercepts (higher KM) at increasing inhibitor concentrations, 
as a pure GSK-3β competitive inhibitor.  
These results are in agreement with patterns obtained with the same enzyme in the fluorescence 
or radiometric method [27]. Replots of the slope versus the concentration of inhibitor gave  
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estimate of the competitive inhibition constant (Ki), in agreement with data reported in 
literature for the GSK-3β FRET-based Z`-LYTETM technology inhibition. The Ki value of 96 
nM obtained with the UHPLC method, based on ADP determination was therefore found to 
well correlate with the value reported in the literature [27].  
The proposed new UHPLC method was further validated determining the IC50 value of the 
EC7 (see Fig. 5c for structure) a  non-classical inhibitor recently synthesized by the research 
group of Milellli A.  as a GSK-3β inhibitor competitive for the substrate and endowed with a 
micromolar inhibitory potency. For this compound we obtained a IC50 value of 9.51 ± 0.13 µM 
and 5.14 ± 0.11 µM by luminescence and UHPLC assay respectively. 
 
 
 
Fig. 8 Kinetic study of Tideglusib mechanism of GSK-3β inhibition. Overlaid Lineweaver–
Burk reciprocal plots of GSK-3β initial velocity at increasing substrate concentration (0.015-
0.125 mM) in the absence and in the presence of Tideglusib (0-200 nM) are shown. Lines were 
derived from a weighted least-squares analysis of the data points. Tideglusib competitive 
mechanism of action is confirmed by all inhibitor curves having the same y-intercept i.e. the 
same Vmax. 
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4. Conclusions 
The obtained results indicate that the UHPLC method can be used for the on-line screening of 
new potential GSK-3β inhibitors. It is remarkable the time reduction for such a determination: 
a chromatographic run of 2 min gives a preliminary indication of the inhibitors potency. 
Considering  that the development of new inhibitors require a large number of compounds to 
be tested for the lead selection and optimization, provided that an autosampler is put on-line, 
hundreds of compounds can be processed in continuous. Due to these peculiarities, this method 
can be considered suitable for high-throughput screening (HTS) in drug discovery. 
This new methodology results more feasible than those based on radiolabeled ligands or on 
FRET technologies. Moreover, it offers the opportunity of overcoming the luminescence assay 
related drawbacks to the indirect determination of kinase activity (it is based on not hydrolyzed 
ATP quantification by a second enzyme); a too high substrate conversion, that made this assay 
not suitable for kinetic purpose; the detection of false negative, due to the possibility of test 
compounds to interact with luciferase or to absorb luminescent emission.  The UHPLC method 
gives the opportunity of directly quantify ADP as reaction product. It is suitable for HTS 
without the risk of detecting false results. Furthermore the determination of kinetic parameters 
is also possible. This is of great interest in the drug discovery process of GSK-3β inhibitors 
because of the lack of non-ATP-competitive compounds. The new method results also 
advantageous in terms of costs and time since there is no need of a second enzyme, the analysis 
time is very short and the process can be automatized by autosampler employment. 
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CHAPTER 2 
 
 
 
 
 
 
Hypothesis of direct changing of the histones acetylation 
level upon GSK-3β regulation and its implication in 
Alzheimer Disease.  Targeted LC-MS/MS approach for 
quantification of lysine acetylation in histones.   
 
 
 
 
 
 
 
 
 
 
. 
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1. Introduction  
Increased GSK-3β signalling, as found in AD, leads to tau hyperphosphorylation [[1-2], which 
is a prerequisite of the formation of neurofibrillary tangles (NFT), and  also plays a direct role 
in several features of AD such as enhancing toxic amyloid peptide production. Another class 
of proteins involved in AD are histones, which are found in the nuclei of almost all eukaryotes 
and package DNA into nucleosomes. Histone proteins can be decorated with post-translational 
modifications (PTMs), such as acetyl-, methyl-, and phosphoryl- groups at distinct amino acid 
residues. These modifications are mainly located in the N-terminal tails of histones that 
protrude from the core nucleosome structure. The most thoroughly studied PTM is the 
acetylation of four universally conserved lysine residues K5, K8, K12, and K16 located within 
the amino-terminal tail of histone H4, which plays a role in the epigenetic regulation  in  
diseases such as cancer and Alzheimer disease (AD).  Histone acetylation in particular has been 
shown to be important both in hippocampal long term potentiation (LTP) and memory 
formation in mice and both aging and Alzheimer Disease are associated with a loss of histone 
acetylation (H4) [3] [4] [5]. Histone acetylation is catalysed by histone acetyl transferases 
(HATs), whereas the reverse reaction is catalysed by histone deacetylases (HDACs). HATs 
and HDACs are classified into several families that are often conserved from yeast to humans 
[6]. Actually, it is well established that pharmacological inhibitors of HDACs are protective in 
various in vivo models of neurodegenerative disease and HDAC3 was identified as a protein 
with cell selective neurotoxic activity [7] [8]. Moreover, HDAC3 was identified as a 
downstream target of GSK3-β. Indeed, HDAC-3 was found to be directly phosphorylated by 
GSK-3β and protection against HDAC-3-induced neurotoxicity was achieved by the inhibition 
of GSK-3β. Furthermore, neurotoxicity by HDAC-3 was inhibited by activation of the IGF-
1/Akt signalling pathway, which in turn inhibits GSK3-β activity and protects against cell death 
in various models of neurodegenerative disease [8].  Consequently, histones deacetylation is 
considered a molecular hallmark of neurodegeneration in addition to those of NFT and toxic 
amyloid peptide.  
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2. Proposal. Considering these findings, herein we hypothesize that GSK-3β could be 
directly involved in the regulation of histone acetylation through HDAC protein. Our 
hypothesis accounts that inhibition of GSK-3β, which leads to reduced HDAC activity [8], 
could restores the acetylation level in histones, protecting against neurodegeneration (see 
Figure 1 for a rational scheme of this hypothesis).  Interestingly GSK-3β could be highly 
considered a critical node in the progression of AD and targeting its inhibition could lead to 
the inhibition of NFT and peptide β-amyloid [9] and to the restoring of histone acetylation level 
necessary for normal neuronal activity. 
 
 
 
Figure 1. Line A. GSK-3β is a kinase constitutively active in cell (red rows) and upon Akt 
signalling pathway or subministration of its specific inhibitors is down regulated (blue rows). 
HDAC3 is directly phosphorylated by GSK-3β, and its inhibition protects against HDAC-3 
induced neurotoxicity. Line B. Histone acetylation has been shown to be crucial in 
hippocampal long term potentiation (LTP) and memory formation in mice and both aging and 
AD  pathology are associated with a loss of acetylation at the N-terminal tail of H4 (red rows). 
Herein we hypothesize that GSK-3β could be directly involved in the regulation of histone 
acetylation through HDAC (Blue rows in line B and dashed row in between line A and B). 
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Our proposal is to exploit the well-known GSK-3β inhibitor SB-415286, in order to trigger 
down-regulation of GSK-3β kinase activity and to monitor changes in histone H4 acetylation 
from murine primary neurons. SB-415286 enhances neuronal cell survival by protecting both 
central and peripheral nervous system neurons in culture from death and this action was found 
to be correlated with inhibition of GSK-3β activity [10]. Further treatment of murine cerebellar 
granular neurons (CGNs) with SB-415286 blocked toxicity induced by HDAC3 (histone 
deacetylase 3), an enzyme that deacetylates lysine residues on histones [8].  
Unlike with cell lines that provide an unlimited supply of homogeneous cells, the preparation 
and culture of primary cells is much more challenging and this is especially true for neuronal 
cells. Neuronal primary cell cultures are deathly and hence the number of cells available for 
experiments is much more limited [11]. Therefore, we developed (described in Chapter 3) a 
targeted liquid chromatography mass spectrometry (LC-MS) method for the site-specific 
quantification of lysine acetylation in the N-terminal region of histone H4 from macrophage-
like cell line RAW 264.7 by administrating well- known HDAC inhibitors with the perspective 
to apply the method on murine primary neurons and by administrating GSK-3β inhibitors as 
SB-415286. 
Accomplishing the project, herein presented, may lead to innovative therapies for targeting the 
pathology of AD, as well as an increased understanding of how epigenetic mechanisms, such 
as histone acetylation, could be related to the GSK-3β signalling pathway through HDAC 
proteins.  
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CHAPTER 3 
 
 
 
 
 
 
 
Site-specific quantification of lysine acetylation in the N-
terminal tail of histone H4 using a double labeling, targeted 
UHPLC MS/MS approach. 
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3.1 Abstract 
 
 
We developed a targeted liquid chromatography - tandem mass spectrometry (LC-MS/MS) 
method for the site-specific quantification of lysine acetylation in the N-terminal region of 
histone H4 by combining chemical derivatization at the protein and at the peptide level with 
digestion using chymotrypsin and trypsin. Unmodified ε-amino groups were first modified 
with propionic acid anhydride and the  derivatized protein digested with trypsin and 
chymotrypsin. The newly formed peptide N-termini were subjected to a second derivatization 
step with d6- (heavy) or d0- (light) acetic acid anhydride. Samples were mixed at different ratios 
and peptides monitored by multiple reaction monitoring (MRM) LC-MS/MS. The method was 
validated in terms of linearity (R2 ≥ 0.94), precision (RSD ≤ 10%) and accuracy (≤ 27%) and 
used to assess the effect of the histone deacetylase (HDAC) inhibitors SAHA and MS-275 in 
the murine macrophage-like cell line RAW 264.7.  SAHA and MS-275 showed site-specific 
effects on the acetylation levels of K5 and K8 with the K5(Ac)-K8 and K5-K8(Ac) peptides 
increasing 2.5-fold and 5-fold upon treatment with SAHA and MS-275, respectively. Assessing 
lysine acetylation in a site-specific manner is important for gaining a better understanding of 
the effects of HDAC inhibitors and for clarifying disease mechanisms where lysine acetylation 
plays a role. 
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3.2 Introduction 
 
In eukaryotes, the basic repeating unit of chromatin is composed of 147 bp of DNA wrapped 
around an octamer of two molecular groups of four histone core proteins: H2A, H2B, H3 and 
H4. The core histones (~11-17 kDa) are basic proteins with a globular domain and a flexible 
N-terminal extension protruding from DNA, referred to as the N-terminal tails. The N-terminal 
regions of histones are affected by different enzyme–mediated post-translational modifications 
(PTMs) that change the accessibility of DNA to transcription factors and subsequent protein-
protein interactions. In particular, acetylation of K5, K8, K12, and K16 in the N-terminal tail 
of histone H4, have been described to play an important role in the epigenetic regulation of 
cellular events with relevance for diseases like cancer and Alzheimer’s Disease (AD).  For 
example, histone acetylation has been shown to be crucial in hippocampal long term 
potentiation (LTP) and memory formation in mice and both aging and AD  pathology are 
associated with a loss of acetylation at the N-terminal tail of histone H4[1,2]. Therefore, 
quantification of histone acetylation on individual lysine residues is of crucial importance to 
understanding their role in cell biology and disease mechanisms. Next to this, quantifying 
histone acetylation will assist in understanding the effects of drugs such as HDAC inhibitors, 
many of which are currently in clinical development.  
One of the challenges in quantifying the level of acetylation at individual lysine residues in the 
N-terminal tail of histone H4 is the occurrence of multiple lysines within a short stretch of 
amino acids. While immunological approaches are useful to investigate histone modification 
patterns, it is technically challenging to generate antibodies that can distinguish between 
closely related epitopes[3]. Mass spectrometry (MS) has emerged as a powerful method to 
characterize histone PTMs complementary to antibody-based approaches [4].  
Currently there are two complementary approaches in proteomics; the top-down and the 
bottom-up approach. In bottom-up, proteins of interest are first digested with a proteolytic 
enzyme and the resulting peptides analyzed by HPLC-MS/MS whereas in top-down the entire 
protein or a large fragment thereof is analyzed by HPLC-MS/MS [5]. While the top-down 
approach opens the possibility to gain an overview of different forms of a protein due to post-
translational modifications (PTMs), it has certain limitations and presents significant 
challenges. Fragmentation efficiency of high-molecular weight ions is poor even though 
fragmentations induced by electron capture dissociation (ECD) or electron transfer dissociation 
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(ETD) are more efficient than the most widely used collision-induced dissociation (CID). 
Further challenges are the fact that large precursor ions are distributed across many charge 
states, reducing overall sensitivity of the top-down approach. Combined with the current lack 
of highly efficient chromatographic separations for proteins when compared to UHPLC of 
peptides and the need for high-resolution, expensive mass spectrometers, renders the top-down 
proteomics approach less suitable for the quantitative bioanalysis of protein modifications in 
complex mixtures. Nevertheless, it is to be expected that top-down protein analysis will gain 
ground with the advent of affordable high-resolution mass spectrometers, more efficient 
protein separation techniques and a better understanding of the charging mechanism in 
electrospray ionization.  With the advent of Multiple Reaction Monitoring (MRM) for protein 
analysis with the bottom-up approach, it is possible to address each modification site 
individually on suitable signature peptides.   
Here we describe a targeted LC-MS/MS method for the site-specific quantification of lysine 
acetylation in the N-terminal region of histone H4 using a total histone preparation from the 
murine macrophage-like cell line RAW 264.7.  We labelled at protein level the ε-amino groups 
of lysine residues with propionic acid anhydride causing a mass shift of +56 Da and protecting 
them from further proteolytic digestion. Although there are many examples in the literature 
describing methods for the site-specific quantification of lysine acetylation following the 
scheme of labelling with propionic acid anhydride and proteolytic digestion [6-8], unequivocal 
and direct site-specific quantification is difficult when multiple lysines occur in close proximity 
to each other in a short amino acid sequence. In order to solve this issue, we combined the 
labelling with propionic acid anhydride at protein level with double digestion using  
chymotrypsin and trypsin followed by derivatization of the neo-N-termini of suitable signature 
peptides with with d6- (heavy) or d0- (light) acetic acid anhydride. LC-MS/MS in the multiple 
reaction monitoring (MRM) mode was applied to monitor changes in the acetylation level of 
individual lysine residues upon administration of the histone deacetylase (HDAC) inhibitors 
SAHA and MS-275 to RAW 264.7 cells.  
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3.3 Experimental Section 
 
3.3.1 Chemicals. Formic acid, hydrogen peroxide, chymotrypsin, trifluoroacetic acid 
(TFA), d6 and d0 acetic acid anhydride, propionic acid anhydride, ammonium 
hydrogencarbonate, 1.0 M triethylamine and 16.3 M hydroxylamine were purchased from 
Sigma Aldrich (St. Louis, MO, USA). Trypsin was purchased from Promega (Fitchburg, 
Wisconsin, United States). HPLC supra gradient acetonitrile was obtained from Biosolve 
(Dieuze, France). Triethylammonium hydrogencarbonate buffer, 1 M at pH 8.5, was prepared 
by titration of a 1M triethylamine solution with CO2. Water was purified by a MilliQ 
Advantage A10 Water System (Millipore, Billerica, Massachusetts, USA).  
 
3.3.2. Cell culture and histone isolation. The murine macrophage-like cell line RAW 
264.7 (American Type Culture Collection, Manassas, Virginia, USA) was cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) containing 10 % heat-inactivated fetal bovine 
serum (FBS), 50 IU/mL penicillin, and 50 IU /mL streptomycin at 37 oC in a humidified 
atmosphere containing 5% CO2. Cell culture reagents were purchased from Life Technologies 
(Carlsbad, CA , USA). For the experiments, cells were used until passage 15. One day after 
seeding, cells were treated with the HDAC inhibitors MS-275 (Axon Medchem, Groningen, 
The Netherlands) or suberoylanilide hydroxamic acid (SAHA, Selleckchem, Munich, 
Germany) (see Figure S1, Supporting Information, for structures). Inhibitor stock solutions 
were prepared at 10 mM for MS-275 and 4.1 mM for SAHA, respectively, in 
dimethylformamide (DMF), and subsequently diluted in DMEM culture medium. Cells were 
incubated with 1 µM of MS-275 or 0.41 µM of SAHA for 20 hrs, conditions that were non-
toxic as determined by MTS assays (Figures S-2 and S-3, Supporting Information). As a 
control, cells were treated with 0.01% DMF, corresponding to the same percentage used for 
treatment with inhibitors. Subsequently, cells were harvested, washed with PBS and pelleted 
by centrifugation at 1000 rpm for 5 min. Histones were extracted as previously described[9]. 
Briefly, cell pellets were suspended in 0.5 mL ice cold buffer containing 13 mM EDTA in 10 
mM Tris-Base, pH 7.4. After centrifugation, sulphuric acid 0.4 M was added to the pellet with 
incubation of 1 hr. Acetone was added to the supernatant to a final concentration of 86% and  
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left at -20 oC overnight to precipitate proteins. After centrifugation, acetone was removed and 
the pellet, dried at room temperature, was redissolved in phosphate buffer saline (PBS, PAA 
Laboratories GmbH, Pasching, Austria). Total protein concentration was determined using the 
microBCA assay according to the manufacturer's instructions (Pierce, Rockford, USA). 
Absorbance was measured with a Fluostar Optima plate reader (BMG, Labtech) at 580 nm. A 
bovine serum albumin standard (2 mg/mL, Pierce, Rockford, USA, # 23209) was used to 
calibrate the assay.  
 
3.3.3. Chemical derivatization of enriched histones. 10 µg of enriched and dried 
histones were diluted with 10 µL water and treated with 2.8 µL of 1.5% aqueous (w/v) H2O2 
for 10 min at room temperature to oxidize methionine residues to their sulfoxides[10]. 
Unmodified ε-amino groups were propionylated by adding 9 µL of propionic acid anhydride 
in 60 µL of 1 M triethylammoniumhydrogencarbonate buffer, pH 8.5. The reaction was 
conducted at room temperature for 10 min with mixing at 450 rpm. The obtained samples were 
dried under vacuum (Eppendorf vacuum concentrator, Hamburg, Germany) and dissolved in 
250 mM ammoniumhydrogencarbonate, pH 8.5. Histones were digested in two different ways; 
with trypsin and with a combination of trypsin and chymotrypsin.  Digestion with a 
combination of the two proteases was performed by treating histones for 6 hrs with 7.5 µL of 
chymotrypsin solution (0.2 µg/µL) at 370 C with continuous mixing at 450 rpm and then adding 
2.5 µL of trypsin solution (0.2 µg/µL) for 10 hrs at 370 C. Digestion with only trypsin was 
performed by treating histones with 2.5 µL of trypsin solution (0.2 µg/µL) for 16 hrs at 370 C 
(mixing at 450 rpm for all reactions). The digestions were stopped by adding 70 µL of 1 % 
aqueous (v/v) formic acid and dried under vacuum.  Digests were dissolved by adding 120 µL 
of 1 M triethylammoniumhydrogencarbonate at pH 8.5 followed by acetylation of the newly 
formed free N-termini with 54 µL d0- or d6- acetic acid anhydride at room temperature and 
mixing at 450 rpm for 10 minutes. The reaction was repeated three times to assure 
completeness. The samples were dried and then diluted in 30 µL 250 mM 
ammoniumhydrogencarbonate, pH 8.5. Propionylation or acetylation of hydroxyl containing 
residues was reversed by hydrolyzing the ester bonds with 30 µL of 0.5 mg/mL aq. 
hydroxylamine for 120 min at room temperature with mixing at 450 rpm. The obtained samples 
were dried and dissolved in 200 µL of 1% (v/v) aq. formic acid. Changes in histone H4 
acetylation upon HDAC inhibitor treatment were assessed by mixing extracted histones from 
untreated cells (heavy labelled) with histones from inhibitor-treated cells (light labelled) at a 
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1:1 protein ratio. Method linearity was assured by analyzing  control samples labelled with  d0- 
or d6- acetic acid anhydride and mixing them at the following ratios:  0:1;  0.1:1;  0.25:1;  0.5:1;  
0.75:1;  1:1; 1.5:1;  2:1 and 4:1. The final volume of all solutions was 60 µL of which 2 µL 
were injected for LC-MS/MS analysis in the MRM mode. 
 
3.3.4 Targeted LC-MS/MS in the MRM mode.  MRM quantification was performed 
on a nanoAcquity UPLC system with a reversed phase guard column (Trap Symmetry, C18, 
100 Å, 5 µm,  300 µm x 50 mm) coupled to a XEVO TQ-S triple quadrupole mass spectrometer 
equipped with an IonKey interface (Waters, Milford, MA, USA), (HSS T3, 130Å,  1.8 µm, 150 
µm x 10 cm) using positive electrospray ionization (ESI+). The vaporizer temperature of the 
ESI+ source was set to 150 0C, the capillary voltage was 3.2 kV, the cone voltage was 40 V; 
the source offset was 50 V; the cone gas flow was 20 L/hr and the collision gas (argon) flow 
was set at 0.15 mL/min. Two microliters of  sample solution were injected with the autosampler 
that was kept at 10°C and chromatographically separated on the IonKey system at 40°C at a 
flow rate 3 µL/min. Mobile phase A was 0.1 % aq. formic acid (v/v) and mobile phase B was 
0.1 % formic acid in acetonitrile. Gradient elution was started at 5% mobile phase B and 
linearly increased to 100 % B at a slope of 4% B/min. For MRM analysis a set of two peptides 
comprising 8 forms corresponding to different acetylation patterns were monitored for samples 
digested with trypsin and chymotrypsin (Table S-1, Supporting Information) and 1 peptide (16 
different forms) was monitored for samples digested only with trypsin (Table S-2, Supporting 
Information). 
To establish the MRM method, transitions for all peptide forms were selected with the help of 
Skyline (MacCoss Lab, software version 2.6.0.6851) including the following modifications: 
lysine propionylation and N-terminal acetylation with d0- and d6- acetic acid anhydride. Three 
characteristic peptide transitions, that allowed differentiating between different modification 
sites, were monitored for each peptide form with the dwell time set at 10 ms. The most intense 
singly-charged y-fragment ion was selected as quantifier. The corresponding chromatographic 
peak areas were integrated with Skyline and relative quantification based on the d0- /d6- ratio. 
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3.4 Results and Discussion  
 
3.4.1 Methodology. A schematic overview of the methodology to monitor the lysine-
acetylation level in the N-terminal region of histone H4 site-specifically is given in the Fig. 1.  
 
 
 
 
 
Fig. 1. Scheme of the sample preparation procedure for the site-specific quantification of lysine 
acetylation in the N-terminal tail of murine histone H4 obtained from RAW 264.7 cells.  
Cells lysis, histone extraction 
    Oxidation of methionine (H2O2)  
Propionylation of lysine side 
chains (K) with propionic acid 
anhydride in NH4HCO3 pH 8.5 
Enzymatic digestion with trypsin 
or trypsin + chymotrypsin 
Acetylation of peptide N-termini 
with acetic acid anhydride in 
NH4HCO3pH 8.5 
Hydrolysis of O-linked (S,T,Y) 
propyl/acetyl groups with 
hydroxylamine 
Addition of reference standard  
(d6 acetylated)  
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The method starts with extracting histones from cell nuclei to reduce sample complexity. While 
other nuclear proteins, such as ribosomal proteins, are co-extracted, the chosen signature 
peptides from the N-terminus of histone H4 were predicted to be unique. To render our 
methodology suitable for monitoring the acetylation level in methionine-containing signature 
peptides in future applications, we included an oxidation step with hydrogen peroxide in the 
procedure to fully oxidized methionine residues to their corresponding sulfoxides.  Methionine-
containing signature peptides are normally not preferred because they are susceptible to 
varying degrees of oxidation, which may affect precision and accuracy due to poor control of 
the ratio between the non-oxidized and mono-oxidized sulfoxide forms. To avoid such 
complications, we fully oxidized the methionine residue with hydrogen peroxide to its 
sulfoxide as previously described [10]. Propionic acid anhydride has been used as 
derivatization reagent to acylate amino groups at N-termini and the Ɛ-position of unmodified 
or mono-methylated lysines, causing a mass shift of +56 Da and protecting these residues from 
tryptic digestion. Moreover, since the mass difference between a proprionyl (+ 56 Da) and the 
naturally occurring acetyl group on lysine residues (+ 42 Da) is 14 Da, it is possible to 
distinguish between lysines that were acetylated in vivo and those that were chemically 
derivatized. To assure that all free primary amino group were fully propionylated, we repeated 
the proprionylation step 3 times [6-8].  Because of lysine proprionylation, trypsin cuts only 
after arginine residues resulting in a single proteolytic fragment from the amino-terminal tail 
of histone H4 encompassing all four lysine residues ((GKGGKGLGKGGAKR (K5-K16)), 
sequence (sp|P62806|H4_MOUSE histone H4 OS=Mus musculus). The challenge of site-
specific quantification of lysine acetylation at the N-terminus of histone H4 is thus related to 
distinguishing between the acetylation state of K5, K8, K12 and K16. Taking all permutations 
into account, the total number of possible acetylated forms for this peptide is 16 (1 form for 
4K-Ac; 4 forms for 3K-Ac; 6 forms for 2K-Ac; 4 forms for 1K-Ac and 1 form without any 
acetylation).  However, only some of these forms can be unambiguously quantified due to 
overlapping MRM transitions (Table S-2, Supporting Information). In order to resolve this 
problem, we combined propionylation of lysine residues at the protein level with proteolytic 
digestion using a combination of trypsin and chymotrypsin to cleave the peptide 
(GKGGKGLGKGGAKR) also after leucine. Each of the formed peptides, GKGGKGL and 
GKGGAKR, contains two lysine residues leading to four different acetylated forms that can 
be quantified unambiguously because of characteristic MRM transitions (Table S-1, 
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Supporting Information). In order to render the method suitable for relative quantification, we 
performed a second derivatization step after proteolytic digestion by treating the samples with 
either d0- or d6- acetic acid anhydride to incorporate d0- or d3-acetate at the newly formed free 
N-terminal amino groups resulting in mass additions of + 42 Da or  + 45 Da, respectively.  
Since acid anhydrides react also with the hydroxyl groups of threonine, serine and tyrosine, we 
treated the derivatized samples with hydroxylamine for selective hydrolysis of ester bonds and 
restoration of the free hydroxyl groups, making the method suitable to monitor peptides bearing 
these residues [11,12]. Mixing the d0- and d6-labelled samples allowed relative quantification 
of each form of the signature peptides GKGGKGL and GKGGAKR from the N-terminus of 
murine histone H4.  
Fig.2 shows the LC-MS/MS chromatograms of GKGGAKR (quantifier transition (y5+) and 
qualifier transitions (y4+, y3+) monitoring each of the four d0-forms related to the pattern of 
acetylation at K12 and K16. The four forms eluted within a time window of less than two 
minutes and peptides with a higher degree of propionylation eluted at increased retention times 
as expected [13]. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. LC-MS/MS (MRM) analysis of all four possible forms of GKGGAKR due to different 
acetylation patterns (A-D). Three transitions were monitored for each peptide form, 2 qualifiers 
(y 4+, y 3+) and one quantifier (y 5+). A)  MRM d0-GK(+56)GGAK(+56)R;  B)  MRM d0-
50% 
Retention time (min) 
% Peak area 
14.0 
y3+ 
B-C 
D 
0% 
A 
12.5 13.0 13.5 
y5+ 
y4+ 
C 5% 
0% 
5% 
0% 
D 
100% 
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GK(+42)GGAK(+56)R;  C)  MRM d0-GK(+56)GGAK(+42)R;  D)   MRM d0-
GK(+42)GGAK(+42)R. Circle C:  enlargement of the MRM trace of d0-
GK(+56)GGAK(+42)R, which is  present at lower intensity and overlaps with the MRM trace 
of d0-GK(+42)GGAK(+56)R (B). Circle D: enlargement of the MRM trace of d0-
GK(+42)GGAK(+42)R (D).  Black traces y 5+; red traces y 4+; blue traces  y 3+ (see Table S-
1 for details). 
 
 Surprisingly, almost all MRM LC-MS/MS chromatograms for different transitions showed 
double peaks as shown in Figure S-4 (Supporting Information). Since double peaks were also 
found for peptides without lysine residues, we hypothesized that they originated from chemical 
derivatization of the N-terminus with acetic acid anhydride after proteolytic digestion due to 
racemization of the C-terminal amino acid via oxazolone formation[14,15] (for more details 
see Figures S-5 and S-6, Supporting Information, and the accompanying text). The method 
may be extended to monitor lysine acetylation in other regions of histone H4, other histones or 
other proteins that may be acetylated such as the transcription factor NF-ƙB.  It must, however, 
be considered that MRM on quadrupole mass analyzers has limited mass resolution compared 
to high-resolution mass analyzers (e.g. TOF or Orbitrap).  This implies, for example, that lysine 
trimethylation (+ 42.04 Da) cannot be distinguished from lysine acetylation (+42.01 Da).    
Although   trimethylation is not a known modification at the N-terminus of histone H4, it may 
interfere at other sites. In this case synthetic peptides carrying the anticipated modification will 
have to be used to ascertain that the proper signature peptide is being monitored, since the 
retention times of peptides containing acetylated versus trimethylated lysine residues will 
differ.   
 
3.4.2 Method Validation. The method was validated with respect to precision and 
accuracy by mixing the (d0-/d6-)-labelled histone H4-derived signature peptides at ratios 
ranging from 0:1 to 4:1. Regression lines were linear across the measured range with 
correlation coefficients of 0.94-0.98 (Table S-3, Supporting Information) and the retention 
times were similar for both d0- and d6- labelled peptides (see Figure S-4, Supporting 
Information). Intra-day and inter-day precision for histone H4-derived peptides after combined 
trypsin and chymotrypsin digestion was determined at two (d0-/d6-) ratios, analyzing six 
replicates within the same day or spread over three different days. The relative standard 
deviation for the inter-day precision was below 0.26% for the retention time (< 0.16 sec) and 
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below 10.1% with respect to peak area (Tables 1 and 2). Accuracy of the method was estimated 
to be better than 27% by comparing peak areas of peptides labelled with d0- and d6- acetic acid 
anhydride and mixed at a 1:1 ratio (Table S-4, Supporting Information).  
 
 
 
Measured peptide forms 
 
Average  
Peak Area 
(n=18)
 
Relative Standard 
Deviation (%)
 
[+d0-/ d6-]GK[+56.0]GGK[+56.0]GL 
0.452
 
0.18
 
[+d0-/ d6-]GK[+56.0]GGAK[+56.0]R 
0.441
 
0.55
 
[+d0-/ d6-]GK[+42.0]GGK[+56.0]GL 
0.502
 
3.15
 
[+d0-/ d6-]GK[+56.0]GGK[+42.0]GL 
0.493
 
10.09
 
[+d0-/ d6-]GK[+42.0]GGAK[+42.0]R 0.540 
0.13
 
[+d0-/ d6-]GK[+42.0]GGAK[+56.0]R 0.498 
3.44
 
[+d0-/ d6-]GK[+56.0]GGAK[+42.0]R 0.489 
0.64
 
   
[+d0-/ d6-]GK[+56.0]GGK[+56.0]GL 
0.215
 
2.46
 
[+d0-/ d6-]GK[+56.0]GGAK[+56.0]R 
0.212
 
0.69
 
[+d0-/ d6-]GK[+42.0]GGK[+56.0]GL 
0.270
 
6.24
 
[+d0-/ d6-]GK[+56.0]GGK[+42.0]GL 
0.268
 
6.39
 
[+d0-/ d6-]GK[+42.0]GGAK[+42.0]R 0.264 
1.98
 
[+d0-/ d6-]GK[+42.0]GGAK[+56.0]R 0.241 
3.82
 
[+d0-/ d6-]GK[+56.0]GGAK[+42.0]R 0.236 
0.60
  
 
Table 1. Precision of peak areas for histone H4-derived peptides after chymotrypsin and 
trypsin digestion analyzing six replicates spread over three different days. The levels refer to 
the following (d0-/d6-) mixing ratios: 0.5:1 (upper part) and 0.3:1 (lower part).  
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 Measured peptide forms
 
Average 
Retention 
time 
(n=18) 
Relative 
Standard 
Deviation 
(%) 
[+d0-/ d6-]GK[+56.0]GGK[+56.0]GL 
17.688
 
0.028
 [+d0-/ d6-]GK[+56.0]GGAK[+56.0]R 
13.610
 
0.000
 
[+d0-/ d6-]GK[+42.0]GGK[+56.0]GL 
16.848
 
0.010
 [+d0-/ d6-]GK[+56.0]GGK[+42.0]GL 
17.077
 
0.044
 [+d0-/ d6-]GK[+42.0]GGAK[+42.0]R 12.781 
0.096
 [+d0-/ d6-]GK[+42.0]GGAK[+56.0]R 13.176 
0.039
 [+d0-/ d6-
]G]K[+56.0]GGAK[+42.0]R 
13.180
 
0.000
 
   
[+d0-/ d6-]GK[+56.0]GGK[+56.0]GL 
17.694
 
0.045
 
[+d0-/ d6-]GK[+56.0]GGAK[+56.0]R 
13.611
 
0.014
 
[+d0-/ d6-]GK[+42.0]GGK[+56.0]GL 
16.853
 
0.034
 
[+d0-/ d6-]GK[+56.0]GGK[+42.0]GL 
17.091
 
0.265
 
[+d0-/ d6-]GK[+42.0]GGAK[+42.0]R 12.780 
0.117
 
[+d0-/ d6-]GK[+42.0]GGAK[+56.0]R 13.167 
0.101
 
[+d0-/ d6-]GK[+56.0]GGAK[+42.0]R 13.181 
0.015
 
 
 
Table 2. Precision of retention times for histone H4-derived peptides after chymotrypsin and 
trypsin digestion analyzing six replicates spread over three different days. The levels refer to 
the following (d0-/d6-) mixing ratios: 0.5:1 (upper part) and 0.3:1 (lower part).  
 
3.4.3 Evaluation of HDAC inhibitors. MS-275 and SAHA are two structurally distinct 
orally active HDAC inhibitors that are in clinical use (SAHA for cutaneous T-cell lymphoma) 
or are currently being studied in clinical trials for the treatment of certain types of cancer[16], 
inflammation[17], viral infections[18] and neurodegeneration[19]. We applied the developed 
methodology to determine the site-specific effect of MS-275 and SAHA on the acetylation 
status of K5, K8, K12 and K16 in the N-terminal region of histone H4 upon administration to 
RAW 264.7 murine macrophages.  Macrophages play a key role in inflammatory responses, 
and while the treatment of inflammatory diseases is a potential area of application of HDAC 
inhibitors, the effect of HDAC inhibitors on the site-specific acetylation of histones in 
macrophages has not been reported.  SAHA was administrated at 0.41 µM (limited by cellular 
toxicity) and MS-275 at 1 µM, both concentrations that are above the IC50 values of these 
inhibitors for class I HDACs except for HDAC8 in the case of MS-275 (Table S-5, Supporting 
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Information). A histone extract from untreated cells (d6-labelled) was mixed 1:1 with an extract 
from treated cells (d0-labelled) and the d6- to d0- peak area ratios for the peptides GKGGKGL 
(K5-K8) and GKGGAKR (K12-K16) monitored the different peptide forms to assess changes 
in lysine acetylation levels. Treatment of RAW264.7 cells with MS-275 and SAHA resulted in 
increased acetylation at all lysine residues (Figure 3). Treatment with MS-275 led to a 5-fold 
increase in acetylation at K5(Ac)-K8 and K5-K8(Ac), respectively, while this increase was 
about 2.5-fold for SAHA. Acetylation of K12(Ac)-K16 and K12-K16(Ac) was increased by 
approximately 2-2.5-fold for both inhibitors (p <0.05). The fully acetylated forms were not 
detected. 
The higher level of K5(Ac)-K8 and  K5-K8(Ac) for MS-275-treated cells is in agreement with 
previous findings, albeit in different cells, indicating that treatment with this inhibitor leads to 
more robust hyper-acetylation than with SAHA[20,21].  
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Fig. 3. Effect of the HDAC inhibitors MS-275 (1 µM) and SAHA (0.41 µM) on lysine 
acetylation in the N-terminal tail of murine histone H4 upon administration to RAW264.7 cells. 
0.01 % DMF was included as control to mimic the effect of the solvent on histone acetylation. 
Acetylated lysine residues are indicated (Ac). The standard deviation relates to three 
independent biological replicates each analyzed twice. Statistically significant differences (p < 
0.05) were found when comparing each monitored form of MS-275- and SAHA-treated 
samples with the corresponding forms from the DMF-treated sample (MS-275 - DMF and 
SAHA - DMF) and comparing each form between the two inhibitor-treated cells (MS-275 - 
SAHA); see Table S-6, Supporting information,  for more details on how the peak areas were 
calculated with the corresponding statistical parameters. 
 
 
3.5 Conclusion 
 
The analytical strategy of chemical derivatization at the protein and at the peptide level, 
combined with digestion using chymotrypsin and trypsin allows differentiating between the 
acetylation levels at individual lysine residues. We demonstrate the utility of this method by 
analyzing changes in the lysine acetylation profile of the N-terminal region of histone H4 upon 
treatment of RAW 264.7 cells with the HDAC inhibitors MS-275 and SAHA showing that MS-
275 results in significantly higher levels of acetylation at K5(Ac)-K8 and K5-K8(Ac) than 
SAHA. The described methodology may be adapted to monitor site-specific lysine acetylation 
changes in other histones as well as in non-histone proteins. 
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Peptide  Forms 
Precursor (m/z) 
1+ charge state  Product (m/z) 
GKGGKGL 
d0-GK[+56.0]GGK[+56.0]GL 770.44 671.41 y6 
d0-G]K[+56.0]GGK[+56.0]GL 770.44 487.29 y5 
d0-GK[+56.0]GGK[+56.0]GL 770.44 430.27 y4 
d0-G]K[+42.0]GGK[+56.0]GL 756.43 657.40 y6 
d0-G]K[+42.0]GGK[+56.0]GL 756.43 487.29 y5 
d0-GK[+42.0]GGK[+56.0]GL 756.43 430.27 y4 
d0-GK[+42.0]GGK[+42.0]GL 742.41 643.38 y6 
d0-GK[+42.0]GGK[+42.0]GL 742.41 473.27 y5 
d0-GK[+42.0]GGK[+42.0]GL 742.41 416.25 y4 
d0-GK[+56.0]GGK[+42.0]GL 756.43 657.40 y6 
d0-GK[+56.0]GGK[+42.0]GL 756.43 473.27 y5 
d0-GK[+56.0]GGK[+42.0]GL 756.43 416.25 y4 
  2+ charge state   
GKGGKGR 
d0-GK[+56.0]GGAK[+56.0]R 414.24 544.32 y5 
d0-GK[+56.0]GGAK[+56.0]R 414.24 487.30 y4 
d0-GK[+56.0]GGAK[+56.0]R 414.24 430.28 y3 
d0-GK[+42.0]GGAK[+56.0]R 407.23 544.32 y5 
d0-GK[+42.0]GGAK[+56.0]R 407.23 487.30 y4 
d0-GK[+42.0]GGAK[+56.0]R 407.23 430.28 y3 
d0-GK[+42.0]GGAK[+42.0]R 400.22 530.30 y5 
d0-GK[+42.0]GGAK[+42.0]R 400.22 473.28 y4 
d0-GK[+42.0]GGAK[+42.0]R 400.22 416.26 y3 
d0-GK[+56.0]GGAK[+42.0]R 407.23 530.30 y5 
d0-GK[+56.0]GGAK[+42.0]R 407.23 473.28 y4 
d0-GK[+56.0]GGAK[+42.0]R 407.23 416.26 y3 
 
 
Table S-1. Overview of all possible acetylated forms of the peptides GKGGKGL and 
GKGGAKR following derivatization with propionic acid anhydride, combined chymotrypsin 
and trypsin digestion and acetylation of the N-terminal region of histone H4 with d-0 acedic 
acid anhydride  The MRM transitions allow the unequivocal quantification of all forms. +42.0 
stands for an acetylation,  +56.0 for  propionylation. and d-0  for acetylation N-terminus with 
acedic acid anhydride (light). 
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Peptide  Forms with zero acetylated lysine 
Precursor 
(m/z)  
Product 
(m/z)      
1 
d0-GK[+56.0]GGK[+56.0]GLGK[+56.0]GGAK[+56.0]R 768.95 955.57      
d0-GK[+56.0]GGK[+56.0]GLGK[+56.0]GGAK[+56.0]R 768.95 898.55      
d0-GK[+56.0]GGK[+56.0]GLGK[+56.0]GGAK[+56.0]R 768.95 785.46      
d0-GK[+56.0]GGK[+56.0]GLGK[+56.0]GGAK[+56.0]R 768.95 544.32      
d0-GK[+56.0]GGK[+56.0]GLGK[+56.0]GGAK[+56.0]R 768.95 487.30      
  Forms with one acetylated lysine          
2 
d0-GK[+42.0]GGK[+56.0]GLGK[+56.0]GGAK[+56.0]R 761.94 955.57      
d0-GK[+42.0]GGK[+56.0]GLGK[+56.0]GGAK[+56.0]R 761.94 898.55      
d0-GK[+42.0]GGK[+56.0]GLGK[+56.0]GGAK[+56.0]R 761.94 785.46      
d0-GK[+42.0]GGK[+56.0]GLGK[+56.0]GGAK[+56.0]R 761.94 544.32      
d0-GK[+42.0]GGK[+56.0]GLGK[+56.0]GGAK[+56.0]R 761.94 487.30      
3 
d0-GK[+56.0]GGK[+42.0]GLGK[+56.0]GGAK[+56.0]R 761.94 955.57      
d0-GK[+56.0]GGK[+42.0]GLGK[+56.0]GGAK[+56.0]R 761.94 898.55      
d0-GK[+56.0]GGK[+42.0]GLGK[+56.0]GGAK[+56.0]R 761.94 785.46      
d0-GK[+56.0]GGK[+42.0]GLGK[+56.0]GGAK[+56.0]R 761.94 544.32      
d0-GK[+56.0]GGK[+42.0]GLGK[+56.0]GGAK[+56.0]R 761.94 487.30      
4 
d0-GK[+56.0]GGK[+56.0]GLGK[+42.0]GGAK[+56.0]R 761.94 941.55      
d0-GK[+56.0]GGK[+56.0]GLGK[+42.0]GGAK[+56.0]R 761.94 884.53      
d0-GK[+56.0]GGK[+56.0]GLGK[+42.0]GGAK[+56.0]R 761.94 771.45      
d0-GK[+56.0]GGK[+56.0]GLGK[+42.0]GGAK[+56.0]R 761.94 544.32      
d0-GK[+56.0]GGK[+56.0]GLGK[+42.0]GGAK[+56.0]R 761.94 487.30      
5 
d0-GK[+56.0]GGK[+56.0]GLGK[+56.0]GGAK[+42.0]R 761.94 941.55      
d0-GK[+56.0]GGK[+56.0]GLGK[+56.0]GGAK[+42.0]R 761.94 884.53      
d0-GK[+56.0]GGK[+56.0]GLGK[+56.0]GGAK[+42.0]R 761.94 771.45      
d0-GK[+56.0]GGK[+56.0]GLGK[+56.0]GGAK[+42.0]R 761.94 530.30      
d0-GK[+56.0]GGK[+56.0]GLGK[+56.0]GGAK[+42.0]R 761.94 473.28      
  Forms with two acetylated lysines          
6 
d0-GK[+42.0]GGK[+42.0]GLGK[+56.0]GGAK[+56.0]R 754.93 955.57      
d0-GK[+42.0]GGK[+42.0]GLGK[+56.0]GGAK[+56.0]R 754.93 898.55      
d0-GK[+42.0]GGK[+42.0]GLGK[+56.0]GGAK[+56.0]R 754.93 785.46      
d0-GK[+42.0]GGK[+42.0]GLGK[+56.0]GGAK[+56.0]R 754.93 544.32      
d0-GK[+42.0]GGK[+42.0]GLGK[+56.0]GGAK[+56.0]R 754.93 487.30      
7 
d0-GK[+56.0]GGK[+42.0]GLGK[+42.0]GGAK[+56.0]R 754.93 941.55      
d0-GK[+56.0]GGK[+42.0]GLGK[+42.0]GGAK[+56.0]R 754.93 884.53      
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d0-GK[+56.0]GGK[+42.0]GLGK[+42.0]GGAK[+56.0]R 754.93 771.45      
d0-GK[+56.0]GGK[+42.0]GLGK[+42.0]GGAK[+56.0]R 754.93 544.32      
d0-GK[+56.0]GGK[+42.0]GLGK[+42.0]GGAK[+56.0]R 754.93 487.30      
8 
d0-GK[+56.0]GGK[+56.0]GLGK[+42.0]GGAK[+42.0]R 754.93 927.54      
d0-GK[+56.0]GGK[+56.0]GLGK[+42.0]GGAK[+42.0]R 754.93 870.52      
d0-GK[+56.0]GGK[+56.0]GLGK[+42.0]GGAK[+42.0]R 754.93 757.43      
d0-GK[+56.0]GGK[+56.0]GLGK[+42.0]GGAK[+42.0]R 754.93 530.30      
  d0-GK[+56.0]GGK[+56.0]GLGK[+42.0]GGAK[+42.0]R 754.93 473.28      
9 
d0-GK[+42.0]GGK[+56.0]GLGK[+42.0]GGAK[+56.0]R 754.93 941.55      
d0-GK[+42.0]GGK[+56.0]GLGK[+42.0]GGAK[+56.0]R 754.93 884.53      
d0-GK[+42.0]GGK[+56.0]GLGK[+42.0]GGAK[+56.0]R 754.93 771.45      
d0-GK[+42.0]GGK[+56.0]GLGK[+42.0]GGAK[+56.0]R 754.93 544.32      
d0-GK[+42.0]GGK[+56.0]GLGK[+42.0]GGAK[+56.0]R 754.93 487.30      
10 
d0-GK[+56.0]GGK[+42.0]GLGK[+56.0]GGAK[+42.0]R 754.93 941.55      
d0-GK[+56.0]GGK[+42.0]GLGK[+56.0]GGAK[+42.0]R 754.93 884.53      
d0-GK[+56.0]GGK[+42.0]GLGK[+56.0]GGAK[+42.0]R 754.93 771.45      
d0-GK[+56.0]GGK[+42.0]GLGK[+56.0]GGAK[+42.0]R 754.93 530.30      
d0-GK[+56.0]GGK[+42.0]GLGK[+56.0]GGAK[+42.0]R 754.93 473.28      
11 
d0-GK[+42.0]GGK[+56.0]GLGK[+56.0]GGAK[+42.0]R 754.93 941.55      
d0-GK[+42.0]GGK[+56.0]GLGK[+56.0]GGAK[+42.0]R 754.93 884.53      
d0-GK[+42.0]GGK[+56.0]GLGK[+56.0]GGAK[+42.0]R 754.93 771.45      
d0-GK[+42.0]GGK[+56.0]GLGK[+56.0]GGAK[+42.0]R 754.93 530.30      
d0-GK[+42.0]GGK[+56.0]GLGK[+56.0]GGAK[+42.0]R 754.93 473.28      
  Forms with three acetylated lysines          
12 
d0-GK[+56.0]GGK[+42.0]GLGK[+42.0]GGAK[+42.0]R 747.92 927.54      
d0-GK[+56.0]GGK[+42.0]GLGK[+42.0]GGAK[+42.0]R 747.92 870.52      
d0-GK[+56.0]GGK[+42.0]GLGK[+42.0]GGAK[+42.0]R 747.92 757.43      
d0-GK[+56.0]GGK[+42.0]GLGK[+42.0]GGAK[+42.0]R 747.92 530.30      
d0-GK[+56.0]GGK[+42.0]GLGK[+42.0]GGAK[+42.0]R 747.92 473.28      
13 
d0-GK[+42.0]GGK[+42.0]GLGK[+42.0]GGAK[+56.0]R 747.92 941.55      
d0-GK[+42.0]GGK[+42.0]GLGK[+42.0]GGAK[+56.0]R 747.92 884.53      
d0-GK[+42.0]GGK[+42.0]GLGK[+42.0]GGAK[+56.0]R 747.92 771.45      
d0-GK[+42.0]GGK[+42.0]GLGK[+42.0]GGAK[+56.0]R 747.92 544.32      
d0-GK[+42.0]GGK[+42.0]GLGK[+42.0]GGAK[+56.0]R 747.92 487.30      
14 
d0-GK[+42.0]GGK[+56.0]GLGK[+42.0]GGAK[+42.0]R 747.92 927.54      
d0-GK[+42.0]GGK[+56.0]GLGK[+42.0]GGAK[+42.0]R 747.92 870.52      
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d0-GK[+42.0]GGK[+56.0]GLGK[+42.0]GGAK[+42.0]R 747.92 757.43      
d0-GK[+42.0]GGK[+56.0]GLGK[+42.0]GGAK[+42.0]R 747.92 530.30      
d0-GK[+42.0]GGK[+56.0]GLGK[+42.0]GGAK[+42.0]R 747.92 473.28      
15 
d0-GK[+42.0]GGK[+42.0]GLGK[+56.0]GGAK[+42.0]R 747.92 941.55      
d0-GK[+42.0]GGK[+42.0]GLGK[+56.0]GGAK[+42.0]R 747.92 884.53      
d0-GK[+42.0]GGK[+42.0]GLGK[+56.0]GGAK[+42.0]R 747.92 771.45      
d0-GK[+42.0]GGK[+42.0]GLGK[+56.0]GGAK[+42.0]R 747.92 530.30      
d0-GK[+42.0]GGK[+42.0]GLGK[+56.0]GGAK[+42.0]R 747.92 473.28      
  Forms with four acetylated lysines          
16 
d0-GK[+42.0]GGK[+42.0]GLGK[+42.0]GGAK[+42.0]R 740.92 927.54      
d0-GK[+42.0]GGK[+42.0]GLGK[+42.0]GGAK[+42.0]R 740.92 870.52      
d0-GK[+42.0]GGK[+42.0]GLGK[+42.0]GGAK[+42.0]R 740.92 757.43      
d0-GK[+42.0]GGK[+42.0]GLGK[+42.0]GGAK[+42.0]R 740.92 530.30      
d0-GK[+42.0]GGK[+42.0]GLGK[+42.0]GGAK[+42.0]R 740.92 473.28      
 
 
Table S-2. Overview of all possible acetylated forms of the peptide GKGGKGLGKGGAKR. 
Trypsin digestion of the N-terminus of histone H4 results in the signature peptide 
GKGGKGLGKGGAKR, which may exist in 16 different acetylated forms. Four forms with 
one acetylated lysine residue, six forms with two acetylated lysine residues, four  forms with 
three acetylated lysine residues, one form with four acetylated lysine residues and one form 
with none acetylated lysine Green highlighting indicates MRM transitions that allow assigning 
acetylated forms unequivocally, while all other transitions are not unambiguous.  +42.0 stands 
for an acetylation, +56.0 for  propionylation  and d-0  for acetylation N-terminus with acetic 
acid anhydride (light) 
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Measured acetylated forms 
Precursor m/z 
(d0- / d6-) Quantifier (m/z) Collision energy (V) 
Retention time, 
(min) R
2 
 
GKGGKGL          
[+d0-/ d6-]GK[+56.0]GGK[+56.0]GL 770.44 / 773.46 487.28 (y5) 27 17.7 0.98 
[+d0-/ d6-]GK[+42.0]GGK[+56.0]GL 756.42 / 759.44 657.39 (y6) 27 17.1 0.94 
[+d0-/ d6-]GK[+56.0]GGK[+42.0]GL 770.44 / 773.46 473.27 (y5) 27 17.1 0.97 
[+d0-/ d6-]GK[+42.0]GGK[+42.0]GL not detected 
GKGGAKR      
[+d0-/ d6-]GK[+56.0]GGAK[+56.0]R 414.24/ 415.75 544.32/ (y5) 14 13.7 0.98 
[+d0-/ d6-]GK[+42.0]GGAK[+56.0]R 407.23/408.74 544.32 (y5) 14 13.2 0,98 
[+d0-/ d6-]GK[+56.0]GGAK[+42.0]R 407.23/408.75 530.30 (y5) 14 13.2 0,98 
[+d0-/ d6-]GK[+42.0]GGAK[+42.0]R 400.22 /401.73 530.30 (y5) 14 12.7 0.95 
 
 
 
Table S-3. Peptides from the N-terminus of murine histone H4 that are formed after combined 
proteolytic digestion with trypsin and chymotrypsin. For each peptide the four forms, 
corresponding to different modification patterns, are given with their corresponding MS/MS 
transitions, collision energies and retention times. Correlation coefficients (R2) relate to 9-point 
calibration curves that were generated by measuring samples that were labelled with d0- or d6-
acetic acid anhydride at different mixing ratios over the range from 0:1 to 4:1. [+d0-/ d6-] stands 
for acetic acid anhydride (light) related to acetic  acid anhydride (heavy). 
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Peptide forms after chymotrypsin and trypsin 
digestion 
Average area  d0-/ d6- 1:1 Accuracy (%) 
GKGGKGL     
[+d0-/ d6]GK[+56.0]GGK[+56.0]GL 1.05 5 
[+d0-/ d6]GK[+42.0]GGK[+56.0]GL 1.19 19 
[+d0-/ d6]GK[+56.0]GGK[+42.0]GL 0.96 4 
GKGGAKR   
[+d0-/ d6]GK[+56.0]GGAK[+56.0]R 1.09 9 
[+d0-/ d6]GK[+42.0]GGAK[+56.0]R 1.13 13 
[+d0-/ d6]GK[+56.0]GGAK[+42.0]R 1.13 13 
[+d0-/ d6]GK[+42.0]GGAK[+42.0]R 1.27 27 
 
 
Table S-4. Accuracy of the method was estimated by comparing the peak areas of peptides 
labelled with d6- or d0-acetic anhydride and mixed at a 1:1 ratio (combined 
chymotrypsin/trypsin digestion). 
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HDAC inhibitor HDACs IC50 (nM) Refs 
  HDAC-1 HDAC-2 HDAC-3 HDAC-8   
SAHA  21-148 144-418 6-509 38-1700 [1-4] 
MS-275  181-300 306-1155 499-8000 2700-
>10000 
[1-3,5] 
 
 
Table S-5. Reported IC50 values for the inhibition of class I HDACs by SAHA and MS-275 
 
 
 
 
 
 
 
 
 
 
 
 K5(Ac)K8 K5-K8(Ac) K12(Ac)-K16 K12-K16(Ac) 
 d-0/d6[K5(Ac)K8]/ 
d-0/d6 [K5-K8] 
d-0/d6 [K5-K8(Ac)]/ 
d-0/d6  [K5-K8] 
d-0/d6 [K12(Ac)-K16]/ 
d-0/d6  [K5-K8] 
d-0/d6 [K12-K16(Ac)]/ 
d-0/d6  [K5-K8] 
 Area average ± SD 
Untreated  1.23 ± 0.15 1.17 ± 0.13 1.13 ± 0.03 1.03 ± 0.01 
DMF 1.37 ± 0.07 1.28 ± 0.08 2.42 ± 0.06 1.32 ± 0.08 
MS-275 5.05 ± 0.34 5.04 ± 0.18 2.42 ± 0.09 3.12 ± 0.03 
SAHA 2.45 ± 0.51 2.49 ± 0.50 1.73 ± 0.28 2.26 ± 0.28 
 
 
 
 
Table S-6. Acetylation levels of peptides GKGGKGL (K5-K8) and GKGGAKR (K12-K16) 
from the N-terminal region of murine histone H4 upon treatment of RAW 264.7 cells with 0.41 
µM SAHA or 1.0 µM MS-275 in comparison to untreated and DMF-treated controls. Results 
are expressed as area ratios between the d0- (treated) versus the d6- (untreated) cells relative to 
the non-acetylated form of GKGGKGL (K5-K8). The standard deviation relates to three 
independent biological replicates each analyzed twice. Acetylation levels between DMF-
treated and inhibitor-treated cells (DMF versus MS-275) (DMF versus SAHA) and between 
MS-275 and SAHA-treated cells (MS -275 versus SAHA) were all significantly different (p < 
0.05). 
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Figure S-1. Chemical structures of SAHA and MS-275  
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Figure S-2. Results of cytotoxicity (MTS) assays for SAHA on RAW264.7 cells. Cells were 
seeded at 7500 cells per well in 96-well plates. On the following day, medium was replaced 
with medium containing SAHA at the given concentrations. After 20 hrs incubation, the MTS 
reagent (Promega, Wisconsin, USA) was added to the wells. After 1 hr of incubation with 
MTS, the absorbance at 490 nm was measured using a plate reader. The amount of absorbance 
at this wavelength is indicative of mitochondrial conversion of MTS, which in turn indicates 
cell viability. The experiment was done in triplicate. No statistical differences were observed 
between untreated cells, or cells treated with SAHA up to a concentration of 0.41 µM while 
viability decreased significantly at higher concentrations. Hence, we conducted our studies 
p < 0.01 and * p < 0.05 compared to untreated cells. 
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Figure S-3. Results of cytotoxicity (MTS) assays for MS-275 on RAW264.7 cells. Cells were 
seeded at 7500 cells per well in 96 wells plates. On the following day, medium was replaced 
with medium containing MS-275 at the given concentrations. After 20 hrs of incubation, the 
MTS reagent (Promega, Wisconsin, USA) was added to the wells. After 1 hr of incubation with 
MTS, the absorbance at 490 nm was measured using a plate reader. The amount of absorbance 
at this wavelength is indicative of mitochondrial conversion of the MTS reagent, which in turn 
indicates cell viability. The experiment was done in triplicate. No statistical differences were 
observed between untreated cells, or cells treated with MS-275 up to a concentration of 3.12 
µM. Hence, we concluded that there is no cytotoxicity of MS-275 to RAW264.7 cells at these 
concentrations.  
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Figure S-4. LC-MS/MS (MRM) analysis of signature peptides from the N-terminus of histone 
H4. Panel A:   Peptide  GKGGAKR (SRM transitions: d0-407.23 m/z 
2+→ d0-544.329 m/z y51+  
and d6-408.74 m/z 
2+ → d6-544.329 m/z y51+) after digestion of histone H4 with chymotrypsin 
and trypsin. Panel B: peptide GKGGKGLGKGGAKR (SRM transitions:  d0-768.94  m/z 
2+ → 
d0-544.32 m/z
1+ and d6- 770.45 m/z 
2+ → d6-544.32 m/z 1+) after digestion of histone H4 with 
trypsin. Blue traces: d0- N-terminally acetylated forms, red traces: d6- N-terminally acetylated 
forms. 
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Figure S-5. Mechanism of formation of two diastereoisomeric peptides via an oxazolone 
intermediate.  Acetic acid anhydride may activate the C-terminal carboxylic acid group in the 
form of a mixed anhydride, which can rearrange to an oxazolone intermediate that is prone to 
racemization. Subsequent hydrolysis of the oxazolone gives two diastereoisomeric peptides 
which can be chromatographically separated resulting in double peaks (see Figure S-4). The 
proposed reaction mechanism suggests a major role for the acetylation conditions and the 
nature of the base that is used during the acetylation reaction, with more nucleophilic bases 
facilitating the rearrangement[6,7]. To find support for this hypothesis, we monitored the 
peptide GKGGKGLGKGGAKR after trypsin digestion of histone H4 by MRM LC-MS/MS. 
Ammonium-ion-containing buffers such as triethylammonium hydrogen carbonate (1 M, pH 
8.5) resulted in  double peaks and repeated additions of acetic acid anhydride led to an increase 
in the intensity of the second peak (Figure S-6, panels B and C). This phenomenon was less 
pronounced upon acetylation in sodium carbonate buffer (1 M, pH 8.5) (Figure S-6, panel A).  
Both findings are in line with the hypothesis that oxazolone formation triggers racemization of 
the C-terminal amino acid as described by Anderson et al. and Bodanszky at al., and that the 
nucleophilicity of the base plays an important role in the racemisation process.  We therefore 
concluded that the observed double peaks are related to diastereoisomeric forms of the same 
peptide and integrated the areas from both peaks for the quantitative analysis of site-specific 
histone H4 acetylations. 
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Figure S-6. Intramolecular rearrangement of N-terminally acetylated peptides via oxazolones 
under different digestion conditions. LC-MS/MS (MRM) analysis of the histone H4-derived 
peptide GKGGKGLGKGGAKR after trypsin digestion and acetylation step. The acetylation 
reaction with d0- acetic anhydride was performed in two different buffers each at 1 M 
concentration and pH 8.5 over increasing reaction times at room temperature.  Panel A: Sodium 
carbonate (3 consecutive treatments with acetic acid anhydride for 10 min).   Panel B:  
Triethylammoniumhydrogencarbonate (3 consecutive treatments with acetic acid anhydride for 
10 min). Panel C:  Triethylammoniumhydrogencarbonate (4 consecutive treatments with acetic 
acid anhydride for 20 min).   
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CONCLUSION  
  
The work of this thesis has been focused on the developing of new analytical methods 
suitable to select and characterize GSK-3β inhibitors in vitro and available to operate in 
high throughput screening (HTS) manner.   
We developed an UHPLC method, which allows monitoring phosphorylation of substrate 
targets from enzyme-based assay and which can be used for the on-line screening of new 
potential GSK-3β inhibitors. The method showed good sensitivity and speed (with a 
chromatographic run less of two minutes) required both for a rapid screening of hit 
compounds and allowing also for a more detailed investigation as the determination of 
potency and mechanism of action.  
We hypothesized that inhibition of GSK-3β could lead to the restoring of acetylation level 
of histones, through down regulation of HDAC proteins and we developed a new method 
for site-specific quantification of the acetylation of the lysine by targeted multiple reaction 
monitoring (MRM) LC-MS/MS.  We demonstrate the utility of this method by analyzing 
changes in the lysine acetylation profile of the N-terminal region of histone H4 upon 
treatment of RAW 264.7 cells with the HDAC inhibitors MS-275 and SAHA. The 
described methodology may be adapted to monitor site-specific lysine acetylation changes 
in other histones as well as in non-histone proteins. By using the developed (MRM) LC-
MS/MS method, selected GSK-3β inhibitors are being tested in murine primary neurons, 
in order to evaluate whether level of lysine acetylation in histones is affected. Upon 
administration of GSK-3β inhibitors, the consequent reduction of the 
hyperphosphorylation of target proteins as Tau and HDAC-3 and the restoring of 
acetylation level in target as histones would make the selected GSK-3β inhibitors more 
specific to counteract the onset of Alzheimer disease. 
Far from being an exhaustive study, this thesis work opens promising perspectives by 
applying the developed methods in view of selection of lead compounds selective for 
targets of Alzheimer disease.  
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